» Articles » PMID: 16185274

Interleukin-10 Downregulates Anti-microbial Peptide Expression in Atopic Dermatitis

Overview
Publisher Elsevier
Specialty Dermatology
Date 2005 Sep 28
PMID 16185274
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Recurrent skin infections in extrinsic atopic dermatitis (EAD) may be because of the suppression of anti-microbial peptide (AMP) expression by interleukin (IL)-4 and IL-13. Twenty to thirty percent of AD, however, are classified as intrinsic atopic dermatitis (IAD). They exhibit normal serum IgE levels, no allergen-specific sensitization, and lower levels of IL-4 and IL-13 than EAD. Both forms of AD have increased propensity to skin infection, suggesting a novel mechanism for infection in IAD. In this study, we observed significantly decreased human beta-defensin (HBD)-2 gene expression in the skin of both IAD (p = 0.010) and EAD (p = 0.004), as compared with psoriasis patients. Conversely, IAD (p = 0.019) and EAD (p = 0.002) skin lesions exhibited elevated IL-10 gene expression when compared with psoriasis. Using primary keratinocytes, we found that the deficiency in AMP expression is an acquired rather than a constitutive defect. Interestingly, neutralizing antibodies to IL-10 augmented the production of tumor necrosis factor-alpha and interferon-gamma by peripheral blood mononuclear cell from AD patients. Additionally, treatment of AD skin explants with anti-IL-10 augmented the expression of both HBD-2 and LL-37. Thus, increased levels of IL-10 may contribute to the AMP deficiency in both IAD and EAD by reducing cytokines that induce AMP.

Citing Articles

Insights into Intrinsic Atopic Dermatitis: immunogenicity, Dysbiosis, and Imaging (Reflectance Confocal Microscopy, Optical Coherence Tomography).

Gavrilita E, Silion S, Bitca M, Tatu A Clin Cosmet Investig Dermatol. 2024; 17:1377-1386.

PMID: 38881699 PMC: 11179656. DOI: 10.2147/CCID.S459096.


Antimicrobial Peptide Loss, Except for LL-37, is not Characteristic of Atopic Dermatitis.

Szabo L, Kapitany A, Somogyi O, Alhafez I, Gaspar K, Palatka R Acta Derm Venereol. 2023; 103:adv9413.

PMID: 37387475 PMC: 10326740. DOI: 10.2340/actadv.v103.9413.


Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.

Hawerkamp H, Fahy C, Fallon P, Schwartz C Skin Health Dis. 2022; 2(2):e99.

PMID: 35677926 PMC: 9168024. DOI: 10.1002/ski2.99.


Optimizing emollient therapy for skin barrier repair in atopic dermatitis.

Elias P Ann Allergy Asthma Immunol. 2022; 128(5):505-511.

PMID: 35065300 PMC: 9979622. DOI: 10.1016/j.anai.2022.01.012.


Atopic dermatitis: molecular, cellular, and clinical aspects.

Salimian J, Salehi Z, Ahmadi A, Emamvirdizadeh A, Davoudi S, Karimi M Mol Biol Rep. 2022; 49(4):3333-3348.

PMID: 34989960 DOI: 10.1007/s11033-021-07081-7.